MARKET

CALA

CALA

Calithera Biosciences Inc
NASDAQ
1.910
+0.005
+0.27%
After Hours: 1.990 +0.08 +4.20% 16:15 11/29 EST
OPEN
2.014
PREV CLOSE
1.905
HIGH
2.014
LOW
1.900
VOLUME
12.61K
TURNOVER
0
52 WEEK HIGH
18.35
52 WEEK LOW
1.900
MARKET CAP
9.29M
P/E (TTM)
-0.0877
1D
5D
1M
3M
1Y
5Y
4D Molecular, Azenta top healthcare gainers; Twist Bioscience, Lumos among losers
Seekingalpha · 11/15 15:00
Ladenburg Thalmann Downgrades Calithera Biosciences to Neutral
Benzinga · 11/15 12:28
SVB Leerink Downgrades Calithera Biosciences to Market Perform, Lowers Price Target to $2
Benzinga · 11/15 09:04
--SVB Securities Downgrades Calithera Biosciences to Market Perform From Outperform, Adjusts Price Target to $2 From $18
--SVB Securities Downgrades Calithera Biosciences to Market Perform From Outperform, Adjusts Price Target to $2 From $18
MT Newswires · 11/15 07:53
Calithera Biosciences Q3 EPS $(2.01) Misses $(1.93) Estimate
Benzinga · 11/14 22:42
BRIEF-Calithera Biosciences Reports Third Quarter 2022 Financial Results
Reuters · 11/14 21:42
Calithera Biosciences reports Q3 results
Seekingalpha · 11/14 21:23
Calithera Biosciences Q3 2022 Earnings Preview
Seekingalpha · 11/13 22:35
More
About CALA
Calithera Biosciences, Inc. is a clinical-stage, precision oncology biopharmaceutical company. The Company is engaged in developing targeted therapies to redefine treatment for biomarker-specific patient populations. The Company is advancing a robust pipeline of investigational, small molecule oncology compounds with a biomarker-driven approach that targets genetic vulnerabilities in cancer cells to deliver new therapies for patients suffering from aggressive hematologic and solid tumor cancers. The Company is opportunistically developing therapeutics outside of oncology to treat diseases with unmet needs, as is the case in cystic fibrosis. The Company's Mivavotinib is a spleen tyrosine kinase (SYK) inhibitor, which targets the constitutively activated B-cell receptor (BCR) pathway in DLBCL and other non-Hodgkin lymphomas NHLs). Its Sapanisertib is a dual target of rapamycin kinase C I/II (TORC1/2) inhibitor that targets a key survival mechanism in KEAP1/NRF2-mutated tumor cells.

Webull offers kinds of Calithera Biosciences Inc stock information, including NASDAQ:CALA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CALA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CALA stock methods without spending real money on the virtual paper trading platform.